First patent from a new patent family granted in China, strengthening the long‑term intellectual property protection for the Company’s lead product candidate Oslo, Norway, 19 March 2026: Oncoinvent (OSE: ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announces […]
Our clients finished off January on a positive note, with some great investment news from Commit, a fundraising milestone from the Novo Nordisk Foundation, and breakthrough AI results from BrightHeart. Novo Nordisk Foundation granted DKK 10 billion (€1.35 billion) to benefit people and the planet in milestone year Following its 100th anniversary in 2024, the […]
“Go west, young man!” Such was the famous advice of Horace Greeley, founder and editor of the (long defunct) New York Tribune, to an acquaintance, Josiah B. Grinnell, in the mid-19th century. Countless individuals, businesses, and industries have since followed that advice – and gone on to strike gold. But when it comes to where […]
· Increasing momentum as we expanded our portfolio of investments, built the team and fostered new partnerships · Three new portfolio company investments and two existing portfolio company financing extensions · First ever Novo Nordisk and Novo Holdings Partnering Day focusing on Cardio Metabolic disease Copenhagen, Denmark, 3 April 2024 – Novo Holdings Asia Investments team today publishes its […]
Novo Holdings, a leading international life science investor, today announced it has participated in a $290 million (USD) strategic financing round of Sangon Biotech. Sangon is a leading provider of life science tools and services, enabling scientists across China to perform state-of-the-art research in hospitals, universities and commercial settings. Read more…
